A Class of Exceptionally Potent HIV-1 Protease Inhibitors
Researchers at Purdue University have designed, synthesized, and evaluated a series of exceptionally potent HIV-1 protease inhibitors for the treatment of AIDS and HIV infections. These compounds represent a novel new class of HIV-1 protease inhibitors that include Tp-THF and other substituted ligands in combination with P1, P1', and P2' ligands. These compounds have demonstrated potency against wild-type viruses as well as multidrug resistant strains of HIV-1. Certain compounds exhibit nearly 100 times more potency than the current, standard HIV therapy.
Exceptionally potent against wild-type and multidrug resistant strains of HIV-1Potency could reduce dosage requirements while maintaining efficacy
Medical/HealthcarePharmaceuticals
Arun GhoshGhosh GroupPurdue Chemistry
United States
None
美國
